Long QT syndrome (LQTS) is a cardiac channelopathy causing increased QT interval, with the risk of torsades de pointes that may progress to ventricular fibrillation. It is essential to be aware of the drugs that increase the QT interval in LQTS and are more likely to provoke torsades de pointes.
It is imperative that b-blockers are continued in patients with LQTS presenting for surgery. I.V. magnesium should be available in case of malignant arrhythmias. Arrhythmogenic right ventricular cardiomyopathy is a progressive disease characterised by replacement of normal myocardium with scar tissue, leading to cardiac failure and potentially fatal ventricular arrhythmias. Haemodynamic stability must be maintained during the perioperative period in patients with arrhythmogenic right ventricular cardiomyopathy. Amiodarone is the drug of choice should ventricular arrhythmias occur.
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syndrome (RWS) and Jervell and LangeeNielson syndrome (JLNS). RWS is autosomal dominant with variable penetrance.
JLNS is much rarer, autosomal recessive, and typically associated with sensorineural deafness, a high chance of cardiac events, and poor response to standard treatment. 1, 2 However, it is estimated that up to 25% of individuals have a proven genetic mutation but a normal QT interval at rest, and the overall prevalence of LQTS is 1:2000e2500. The most common genetic mutations are termed LQT1, 2, and 3, respectively. 1, 3 Symptoms can manifest at any time from birth until adulthood, although most usually in childhood and adolescence. 4 Patients may be diagnosed incidentally or present with seizures, palpitations, or syncope caused by torsades de pointes (TdP), a form of polymorphic ventricular tachycardia. 2, 4 In this condition, most of the time TdP is self-limiting; usually lasting <1 min, but it may progress to ventricular fibrillation leading to SCD. 5 Cardiac events are typically triggered in LQT1 by emotion or exercise (especially swimming), in LQT2 by sudden auditory stimuli. LQT3-related cardiac events more frequently occur during rest or sleep. 2 Left untreated after a first syncopal episode, the mortality rate is as high as 21% but can be reduced to 1% when managed properly. 1 The risk of inducing dangerous perioperative arrhythmias may be minimised by a good self-knowledge of the condition, avoidance of precipitating drugs and compliance with medication.
Diagnosis
The QT interval, corrected for heart rate (QTc), is calculated using Bazette's formula:
The duration of the QT interval corresponds with the time for ventricular repolarisation. Traditionally, a QT c >450 ms in males and >460 ms in females is considered long, but this in its own right is not diagnostic. A scoring system has been devised by Schwartz with a score of !3.5 indicating a high probability of LQTS (Table 1) . 1 Secondary causes of a prolonged QT should be excluded before considering a diagnosis of LQTS.
An identifiable pathogenic mutation in the setting of LQTS is diagnostic. However, genetics are not required for the diagnosis. Serial ECGs, 24 h ambulatory ECG, exercise testing, and adrenaline QT stress testing may aid diagnosis (Fig. 1) .
Differential diagnosis
A detailed history should be obtained to exclude an acquired cause. An exhaustive list of drugs that can prolong the QT can be found at www.qtdrugs.org but Table 2 summarises some of the commonest culprits. 6 Hypokalaemia, hypomagnesaemia, hypocalcaemia, and hypothyroidism all prolong the QT c . Structural heart disease can be associated with LQTS. For example, a dilated left ventricle is a recognised cause of acquired long QT syndrome.
Pathogenesis
LQTS types 1e3 account for >90% of genetically confirmed disease, although 15 genes have so far been identified in autosomal dominant forms. 3, 7 No mutation is currently identified in 20% of clinically diagnosed LQTS. 3 The most commonly affected genes are KCNQ1 (LQT1 accounting for 30e35% of cases) encoding the I Ks potassium channel a subunit, KCNH2 (LQT2; 25e40%) encoding I Kr potassium channel a subunit and SCN5A (LQT3; 5e10%) encoding the I Na voltage gated sodium channel a subunit. 7 The cardiac action potential and ion channels are described in an accompanying article. 8 As described previously, repolarisation is heterogeneous throughout the myocardium. LQTS mutations lead to reduced activity of cardiac potassium channels or increased activity of sodium or calcium channels. These result in prolongation and heterogeneity of the action potential. Repolarisation differences across the myocardium are termed transmural dispersion of repolarisation (TDR). 4 The enhanced TDR in LQTS produces regions susceptible to early after-depolarisations (EADs) and areas for re-entrant circuits. EADs can generate shifting and propagating locations for more EADs resulting in TdP. 9 The increased TDR is the substrate for TdP and this is not always reflected in an increased QT c . The time difference between T peak and end has been advocated as a more accurate reflection of TDR. 10 
Management strategies

Community management
Management in the community (by a cardiologist) is based on balancing the risk of a serious event against the potential complications of some treatments. The annual incidence of suffering a cardiac arrest or sudden death by age 40 yr in the common genotypes is 0.3%, 0.6%, and 0.56% for LQT1, 2, and 3, respectively. 2 Males are typically at higher risk until puberty, at which point the QT c shortens. After this point, females are more likely to have cardiac events. b-Blockers, specifically propranolol or nadolol, are the mainstay of treatment and should be prescribed at maximum tolerated dose in all patients. 1, 3 They are highly effective at reducing mortality in LQT1 but less effective (although still important) in patients with LQT2 and LQT3. 1, 2 Evidence is emerging for the use of sodium channel blockers (mexiletine: a class 1b antiarrhythmic) in addition to b-blockers in selected LQT3 patients. 1 Electrolyte imbalance should be avoided (particularly in patients with LQT2, who are extremely sensitive to hypokalaemia) and drugs that may prolong the QT interval, which have a lower rate of complications as long standing i.v. wires are not required, are now being used in specialist centres. Symptomatic patients with LQTS may benefit from atrial pacing, which can reduce arrhythmic episodes by shortening the QT interval.
Perioperative management
Similar to other hereditary arrhythmias with an infrequent incidence, there is a lack of robust evidence for any specific anaesthetic method. Much of what follows is based on case studies and expert consensus. A patient with LQTS may present in a variety of circumstances: a patient aware of their diagnosis and well optimised by their cardiologist; prolonged QTc identified incidentally at a preoperative visit; and those presenting with aborted SCD. Risk stratification should focus on genotype if known and frequency of cardiac events. Current medications should be reviewed, specifically to ensure that QT-prolonging drugs are avoided. Patients should continue b-blockade throughout the perioperative period, as non-compliance is associated with increased likelihood of arrhythmia, and even a single missed dose is significant. 1, 10 Untreated patients are at high risk of intraoperative arrhythmias, and a cardiologist should be involved in both elective and emergency surgery. 4 All patients should have a 12-lead ECG, which will allow calculation of baseline QTc, and identification of high-risk features such as T-wave alternans. 2, 3 Hypokalaemia, hypomagnesaemia, and hypocalcaemia must be corrected. 5 If present, an ICD should be interrogated and deactivated before surgery with an external means of defibrillation to hand. All team members should be informed of the diagnosis, the potential for lifethreatening arrhythmias and how these should be managed. Efforts to reduce patient stress, a calm environment, and anxiolytic premedication should be considered, especially in genotypes in which emotional stress can provoke arrhythmia. 11 Midazolam can be used safely although information on other benzodiazepines is limited. 4, 5, 11 Perioperatively, the QTc is best monitored in lead II. 4 Sympathetic stimulation should be minimised. Hypothermia lengthens the QT and should be avoided. 10, 11 Intrathoracic pressures should be kept low; Valsalva and recruitment manoeuvres can prolong the QT. 4 Both regional and general anaesthesia are suitable techniques and all local anaesthetic agents can be given safely, although adrenaline should not be added to local anaesthetics. 11, 12 If a patient is deemed particularly high risk, the use of prophylactic magnesium infusion should be considered. 11 In prolonged operations with fluid shifts, electrolyte imbalances should be sought and corrected. Propofol reduces the QT. Thiopental increases the QT but reduces the TDR. 4, 5, 10, 11 Most authors advise avoiding ketamine because of its sympathomimetic properties. 4 All volatile agents prolong the QT, although they have been safely used with isoflurane identified as the most appropriate agent. 4, 10, 11, 13 Succinylcholine prolongs the QT. 4 Of the nondepolarising neuromuscular blockers, only pancuronium has been shown to prolong the QT and to be associated with arrhythmias. 11 The pressor response to intubation leads to prolongation of the QT and this should be attenuated using alfentanil, esmolol, clonidine, or topical lidocaine. 4, 11 Sufentanil and methadone lengthen the QT but other opioids can be used safely. 5 Adrenaline, noradrenaline (norepinephrine), isoprenaline, and ephedrine can all prolong the QT and should not be used unless absolutely necessary whilst metaraminol appears not to affect the QT. 11 Phenylephrine does not increase the TDR. 12 Droperidol, domperidone, and 5HT 3 antagonists should be avoided, although ondansetron has been used without incident. 4, 5, 10, 11, 13 Oxytocin transiently prolongs the QT c and has been associated with ventricular arrhythmia and should only be used with caution after riskebenefit discussion and injected slowly. 12 There is no published information on other uterotonics. 11 Conventional reversal of neuromuscular block induces a tachycardia, increases the QT and should be avoided. 4, 5, 11, 13 Sugammadex appears safe in low and supranormal doses. 14 Emergence should prompt increased vigilance as it has been identified as a point of increased risk of precipitating arrhythmias. 13 Consideration might be given to performing extubation under deep anaesthesia as this may reduce sympathetic stimulation. 4 Recovery should take place in a calm and quiet environment. 5 Cardiac monitoring should be continued for at least 24 h after operation, including during transfers. 4 b-Blockade must be continued and if necessary converted to the parenteral route. Analgesia should be optimised, care should be taken to avoid drugs that prolong QT, and electrolytes kept within normal limits.
ICU management
A patient who presents with LQTS-related cardiac arrest will require a number of the conventional postarrest treatments and relevant investigations including temperature management, blood pressure and carbon dioxide control. Prevention of further arrhythmias is important, and continued bblockade and magnesium management should be instituted if possible. The pharmacological principles highlighted above should be followed. Polypharmacy is likely during ICU care, and care should be taken with all drugs prescribed (for example many prokinetics and antibiotics prolong the QT). The need to provide adequate perfusion pressures and cardiac output must be balanced against the risk of provoking arrhythmias. Management of this scenario should be made pragmatically on a case-by-case basis. One tried option is to use a combination of noradrenaline (or metaraminol) with a low dose of b-blocker. Dobutamine, levosimendan, and milrinone increase the QT, but the effects of the latter may be ameliorated by concurrent b-blockade.
15,16
Withdrawal of sedation (and assessment of neurological outcome) can be arrhythmogenic, and maximal b-blockade is again a key component. Transvenous pacing at rates >90 beats min À1 (preferably atrial-based) can be used to shorten the QTc and reduce TdP recurrence in emergency circumstances.
Management of TdP
TdP is usually self-limiting but can be associated with severe haemodynamic compromise and can deteriorate to ventricular fibrillation (VF). Should this occur, standard advanced life support management should be followed. A magnesium sulfate infusion of 30 mg kg À1 over 2e3 min (which can be repeated every 15 min) followed by 2e4 mg min À1 can prevent further episodes of TdP, even if serum concentrations are normal, although these should be monitored. 4, 11 Magnesium infusions have no effect on the QT interval but prevent TdP. Amiodarone should not be used. As above, transvenous temporary pacing to increase the heart rate to >90 beats min À1 is effective at reducing TdP recurrence.
Arrhythmogenic right ventricular cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disease principally affecting the right ventricle, leading to progressive replacement of healthy myocardium with fibro-fatty scar tissue. It can result in ventricular arrhythmias and SCD. 17 ARVC is one of the commonest causes of SCD in young adults and athletes and is implicated in a significant proportion of perioperative deaths in apparently healthy patients. 18, 19 The prevalence is estimated to be 1 in 5000, although apparently higher in some areas of Italy, Greece, and Germany. 17, 20 An autosomal dominant inheritance pattern but with variable penetrance and limited expression leads to an underestimation of its true prevalence. 17, 18, 21 A less common autosomal recessive form exists, associated with palmo-plantar keratosis, woolly hair and a more severe cardiomyopathy, called Naxos syndrome. 18, 22 Initially, patients with ARVC are asymptomatic with little or no myocardial tissue replacement. Over time, and accelerated by myocardial mechanical stress, fibro-fatty tissue replaces normal contractile tissue. With disease progression, ventricular arrhythmias and cardiac failure become more likely. ARVC most commonly presents between the ages of 20 and 40 yr with males typically exhibiting a more severe phenotype. 17, 23 Patients experience palpitations, atypical chest pain, dyspnoea or syncope, although first presentation may be with SCD because of ventricular tachycardia (VT) or VF. 11, 18, 20 Heart failure develops in approximately 25% of patients. 22 Despite its name, it is important to note that ARVC can progress to affect both ventricles or be left dominant. 21, 23 Annual mortality (related to ventricular failure or SCD) is estimated to range from 0.08% to 3.6%, although, with early recognition and adequate treatment, it is <1%.
24
Diagnosis
Unfortunately, no single test is applicable, so the 2010 International Task Force developed likelihoods: definite, borderline, or possible. 21 These take into account family history in a first-degree relative, witnessed evidence of VT and other typical ECG abnormalities, the degree of fibro-fatty replacement of the RV at tissue characterisation and evidence of global or regional dysfunction with imaging. The ECG may demonstrate the following features: (iv) epsilon waves in leads V1 and 2 (low-amplitude potentials between the end of the QRS complex and the beginning of the T-wave) (Fig. 2) ; (v) VT of LBBB morphology with a negative or indeterminate axis in leads II, III and aVF and positive in lead aVL; (vi) late potentials and filtered QRS duration !114 ms on signal averaged ECG.
T-wave inversion in V1e3 in those >14 yr is only seen in health in 4% of women and 1% of men and so in this patient group is a useful sign. 21 Twenty-four hour ambulatory ECG allows quantification of ventricular extrasystoles and VT. Imaging such as echocardiography and cardiac MRI can determine global or regional dysfunction, presence of aneurysms, and increased right ventricular outflow tract dimensions (Fig. 3) . 17, 21, 25 As only 50% of patients with ARVC have an identifiable gene, genetic testing is not currently required or recommended. 17 
Pathogenesis
Desmosomes are protein complexes that bind cardiac myocytes providing structural support. 22 Mutations in the genes encoding protein components of the desmosome appear to be the most common aetiology for ARVC: plakophilin-2 (PKP2, 10e45%), desmoplakin (DSP, 10e15%), desmoglein-2 (DSG2, 7e10%), and desmocollin-2 (DSC2, 2%). 17 These genetic variants have fragile cellular adhesion under mechanical stress. This leads to myocyte shearing and apoptosis, and subsequent replacement with adipose tissue and fibrosis. 20 Exercise places disproportionately higher stress on the RV in comparison with the LV, and this is the given explanation as to why the RV outflow tract, the sub-tricuspid area, and the apex are classically the areas most affected. 17, 20 Two nondesmosomal gene mutations have been identified that induce ARVC: the cardiac ryanodine receptor (RYR2) that affects sarcoplasmic calcium release; and transforming growth factor (TGF-b3), which has a role in fibrosis. 18, 20 Risk assessment
Risk assessment is based on clinical history, ECG, and imaging modalities. Previous episodes of aborted SCD or sustained VT confer the greatest risk of further cardiac events. 16 Other factors associated with high risk are evidence of extensive disease and episodes of unexplained syncope (Table 3) . 24, 25 Electrophysiology studies can aid in risk stratification by quantifying the amount of scar tissue involved and whether arrhythmias are inducible.
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General management
Intense sporting activities increases the risk of lifetime events and occurrence of heart failure and so should be avoided. 17, 23, 24 Patients require regular follow up with some advocating patients be seen every 1e2 yr because of the progressive nature of the disease. 17, 25 Patients who develop ventricular failure should be managed with conventional pharmacological therapy using ACE inhibitors, b-blockers, and diuretics. 24, 25 If intracardiac thrombosis occurs long-term oral anticoagulation should be started, but prophylaxis is not recommended.
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Arrhythmia reduction is achieved using a combination of drugs or devices. Amiodarone in combination with a b-blocker or alternatively sotalol are effective at preventing ventricular arrhythmias but may be associated with significant adverse effects. They should be used to improve symptoms or prevent frequent ICD firing. 17,23e25 Endocardial catheter ablation can be effective in the short term but high rates of recurrence mean this is generally only used when frequent VT occurs despite maximal pharmacological therapy. Adjunctive epicardial techniques (in which access is gained through the pericardium) are showing more long-term promise and can be considered in centres with sufficient experience. 17, 24 Patients who have had an episode of unstable sustained VT or VF or with severe systolic dysfunction should have an ICD implanted as it confers a survival benefit in this group in contrast to drug and ablation therapy. ICDs can be considered in patients with repeated stable sustained VT but should not be implanted in lower risk patients because of the complications associated with long-term ICDs. 17, 24, 25 ICDs programmed with antitachycardia pacing can terminate VT without the need for a painful shock. Newer subcutaneous ICDs may, importantly, alter the risk/benefit profile of early implantation particularly in younger patients. In the case of untreatable heart failure or intractable arrhythmias, heart transplantation should be considered. 24 
Anaesthesia
The recommendations surrounding the perioperative care of ARVC are based on a limited evidence base and expert opinion. Unfortunately, it is clear that patients may experience perioperative arrhythmic events and SCD despite previous uncomplicated anaesthesia and apparent good health. 11, 18, 20 SCD can occur at any point from induction of anaesthesia until hours after surgery is completed. 19 Surgery should be deferred, if possible, when there is evidence of poorly controlled symptoms and ongoing arrhythmias in known ARVC. A recent echocardiogram, a 12-lead ECG and 24 h ambulatory ECG, and (when present) an ICD interrogation are useful for risk stratification. Multidisciplinary planning, involving the surgeon, anaesthetist, and cardiologist is essential. 18 The patient should be counselled on the higher risk involved. Antiarrhythmic drugs should be continued. Any ICD should be deactivated just before surgery and reactivated shortly afterwards. The key aims of anaesthesia are to maintain haemodynamic stability, minimise stress, and avoid tachycardia, hypertension, and hypotension.
11,18e20
Benzodiazepine premedication is recommended. 11 In all but the shortest, most minor procedures, we would recommend invasive intraarterial pressure monitoring, with a low threshold for central venous catheterisation and even transoesophageal echocardiography for major procedures with significant blood loss. 20 Most authors advise against the use of pulmonary artery catheters. 18, 20 Propofol and thiopental have been used safely. Theoretically, the haemodynamic profile of ketamine The choice of drug for treatment of hypotension should be determined pragmatically according to the clinical situation.
b-Adrenergic stimulation may provoke arrhythmias and so such agents should be used with caution; a-agonists are less likely to be arrhythmogenic. 11, 19 Sympathetic stimulation should be minimised by ensuring adequate analgesia. Fentanyl has been used repeatedly. 19 Regional techniques can be used safely, although the addition of adrenaline should be avoided, and some recommend avoiding large doses of bupivacaine because of its potential for cardiotoxicity. 11 Epidural anaesthesia has also been administered safely to parturients with ARVC. 25 Perioperative ventricular arrhythmias have been managed with amiodarone, even if the patient is already receiving it.
18,26
Intensive care
Patients can be admitted to intensive care with a multitude of different clinical features. For example, an intracardiac thrombus could result in an embolic cerebral or pulmonary event; ventricular arrhythmias could lead to a cerebral anoxic event; or decompensated heart failure (with or without an intercurrent infection). Because of a lack of evidence and the varied presentations, it is not possible to recommend one particular method for management of patients with ARVC requiring organ support. Methods should be used that maintain haemodynamic stability without inducing arrhythmias.
For example, levosimendan and b-blockers may be less arrhythmogenic than dobutamine in very low cardiac output states. Antiarrhythmic medication must be continued or possibly increased (with involvement of a cardiologist).
Amiodarone, b-blockers, or sotalol are commonly advised.
Conclusions
If left untreated or treated suboptimally, LQTS and ARVC may cause significant perioperative morbidity and mortality in young people. In LQTS, important aspects of care are the identification of those at highest risk, maintenance of maximal b-blockade, and monitoring the QTc perioperatively.
A number of drugs used in anaesthesia and intensive care are associated with QTc prolongation and should be avoided. ARVC is best managed by appropriate pre-or perioperative pharmacological planning involving surgeon, anaesthetist, and cardiologist. Crucially, this involves continuation of appropriate antiarrhythmic drugs (parenterally if required). Common antiarrhythmic drugs used in ARVC include amiodarone, b-blockers, or sotalol. Any ICD will need to be temporarily deactivated during the perioperative period.
In both LQTS and ARVC, evidence is lacking to support one particular anaesthetic technique over another. However, one clear recommendation is to avoid sympathetic stimulation such as during intubation and extubation, and by providing good analgesia. Sympathetic stimulation is associated with arrhythmogenesis in both conditions.
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